exosome News
-
Exosomes News: Creative Biolabs Introduces Exosome Purification Services for Cargo Loading Research
As exosomes can transmit the information of donor cells to recipient cells through the proteins, mRNA, miRNA carried by them, thus to realize the information and material exchange between cells, they have been a hot topic recently as being used as a drug carrier to transport drugs. "Future research may focus on how to improve the cargo loading of exosomes," said the senior scientist from ...
-
Creative Biolabs Upgrades Proteomics Technologies for Exosomal Cargo and Biomarker Research
Exosomes, small lipid bilayer-enclosed particles of endosomal origin, are a subset of extracellular vesicles (EVs) that are secreted by most cell types. They are spherical, bilayered proteolipids and show a diverse mixture of exosomal nucleic acids (mRNA and non-coding RNA), proteins, and lipids, among which exosomal proteins play a key role in the pathological process of various diseases. At ...
-
Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research
Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...
-
Exosome Display Technology for Antibody Generation, Targeted Delivery, and Protein Array Screen
Scientists now have realized that exosomes, representing a novel mode of intercellular communication, contribute to a wide range of biological processes in health and disease including cancer. Especially, growing evidence shows that tumor-derived exosomes play critical roles in cancer. Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer ...
-
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. Management will then host a webcast and conference call at ...
-
Evox Therapeutics Expands Its Exosome Patent Portfolio
Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted a new European patent, EP3706796, to add to its growing patent portfolio. This patent covers exosomes loaded with nucleic acids or ribonuclear protein complexes. The granted claims add to Evox’s patent estate, providing further ...
-
Exosome Services at Creative Biolabs to Accelerate Lung Cancer Research
As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome ...
-
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida. Please see ...
-
CD Genomics Introduces Advanced Exosomal RNA Sequencing Service for Enhanced Molecular Insights
CD Genomics, a leading provider of transcriptomics sequencing solutions, is pleased to announce the launch of its Exosomal RNA Sequencing service. This innovative service is set to provide researchers with comprehensive and accurate analysis of exosomal RNA, facilitating a deeper understanding of their functional significance in various biological processes. Exosomes, small extracellular ...
By CD Genomics
-
Creative Proteomics Launches Advanced Exosome Isolation and Purification Service
Creative Proteomics, a leading provider of proteomics and metabolomics services, is proud to announce the launch of its state-of-the-art Exosome Isolation and Purification Service. This innovative service is designed to meet the increasing demand for high-quality exosomes in the field of biomedical research and therapeutic development. Exosomes, small extracellular vesicles released by cells, ...
-
Creative Proteomics Unleashes the Exosome Untargeted Metabolomics Service
Creative Proteomics, the globally recognized proteomics, metabolomics, and multi-omics service provider, is delighted to introduce its exosome untargeted metabolomics services—a premier-stage offering in their broad catalogue services. Exosomes are tiny extracellular vesicles, hosting a diverse array of molecules including proteins, RNAs, and metabolites. With a diameter ranging between ...
-
CD Genomics’ RNA-Solutions Platform Now Supports Exosomal RNA Research
CD Genomics’ RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Based on rich RNA project experience and leading bioinformatics analytical capabilities, CD Genomics has launched a systematic solution for exosomal RNA research that assists in in-depth identification and functional analysis of exosomal ...
By CD Genomics
-
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022. Please see ...
-
Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
-
Creative Proteomics Lipidomics Launches Exosomes Lipidomics Service to Study the Biological Characteristics of Vesicles
Lipidomics, a division of Creative Proteomics, is committed to providing untargeted lipidomics services, targeted lipidomics services, metabolic flux analysis services, and lipidomics related services for research institutions, biotechnology and pharmaceutical companies. The company continues to accelerate lipidomics research to make contributions in the fields of biopharmaceuticals, population ...
-
Creative Proteomics Lipidomics Announces Exosomes Lipidomics Service to Identify Lipid-based Biomarkers
Lipidomics, a division of Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The product manager has recently announced the fully-developed exosomes lipidomics service to help identify lipid-based biomarkers and unravel its monitoring function in diseases. ...
-
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. Avat Brings Over 25 Years of Business and Commercial Strategy Experience to Capricor Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the ...
-
Bio-Techne Announces Paper Publication in Annals of Oncology
This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne ...
-
INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market
INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is developing a multi-product ...
By INOVIQ Ltd
-
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
CAP-1002 Cell Therapy Programs Pivotal Phase 3, HOPE-3 Trial Initiation Underway- Entered Exclusive Partnership with Nippon Shinyaku for Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in United States- Capricor to Receive Upfront Payment of $30 Million with Additional Milestone Payments of up to $705 Million- Phase 2 INSPIRE Top-Line Data Expected by End of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you